About Topelia
Topelia Aust Limited (ABN 36 652 771 670) is a pioneering, unlisted biotechnology company committed to developing and commercialising its proprietary Antiviral Triple Therapy (ATT), designated TPL101. Building on the experience of successfully commercialising a Triple Therapy for Helicobacter pylori, Topelia's leadership is now channelling their expertise into advancing TPL101, initially aimed at treating COVID-19 infections.
Investment Opportunities and Tax Incentives
As an Early Stage Innovation Company (ESIC), Topelia has provided original investors potential eligibility for tax incentives under Division 360 of the Income Tax Assessment Act 1997. These incentives are designed to encourage investment in innovative Australian companies and include:
- Non-Refundable Tax Offset: Investors may receive a non-refundable carry-forward tax offset equal to 20% of the amount invested in eligible shares, capped at $200,000 per investor and their affiliates combined in each income year.
- Modified Capital Gains Tax (CGT) Treatment: Capital gains on qualifying shares held continuously for at least 12 months and less than 10 years may be disregarded.
Advancing COVID-19 Treatment Strategies
TPL101 is designed to complement existing COVID-19 strategies, functioning alongside vaccines and authorised antiviral treatments. In light of ongoing COVID-19 outbreaks, the emergence of new variants, and challenges such as vaccine hesitancy, there is a critical need for a broader spectrum of safe and effective antiviral therapies.
Innovative Therapeutic Composition
TPL101 combines ivermectin and doxycycline—medications with well-established safety profiles—with zinc in a proprietary fixed-dose formulation. By utilising known, regulator-approved active pharmaceutical ingredients (APIs), the development process for TPL101 is anticipated to be more rapid, cost-effective, and lower risk compared to traditional drug development pathways.
Clinical Development and Regulatory Pathway
Topelia is currently progressing towards conducting its Phase 3 clinical trial for TPL101 and plans to seek approval from the Therapeutic Goods Administration (TGA) in the 2025 calendar year.
Exploring Broader Antiviral Applications
Given its mechanism of action, which targets proteins conserved across various viruses, Topelia intends to investigate TPL101's efficacy against other viral infections. This includes potential applications for Avian influenza and diseases caused by the Flaviviridae family, such as Dengue, Zika, and Yellow Fever.
Topelia Aust Limited remains steadfast in its mission to develop innovative antiviral therapies that address current and emerging global health challenges.
